Holen Sie sich die Stockscreener-App
129.83
3.72%
-5.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$134.84
Offen:
$134.02
24-Stunden-Volumen:
5.93M
Relative Volume:
0.84
Marktkapitalisierung:
$161.19B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.67
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-1.10%
1M Leistung:
+6.87%
6M Leistung:
+7.21%
1J Leistung:
+13.35%
1-Tages-Spanne:
$129.26
$134.97
1-Wochen-Bereich:
$127.88
$137.70
52-Wochen-Spanne:
$107.75
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
129.83 | 161.19B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Gilead Sciences, Inc.'s Stock Price Drops to $129.83, marking a 3.72% Decline: Time to Sell or Buy? - Smartkarma
A Look at Gilead Sciences Inc (GILD) After 3.7% Decline -- GF Va - GuruFocus
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MSN
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement - TradingKey
Gilead Sciences (GILD) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Gilead Sciences (GILD) RBC Capital Markets Global Healthcare Conference 2026 Summary - Quartr
Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Gilead Sciences highlights HIV and oncology pipeline as investors track long-term growth - AD HOC NEWS
Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative - Yahoo Finance
Morgan Stanley Keeps Buy Rating on Gilead (GILD) - Insider Monkey
Gilead Sciences signals steady progress as investors watch pipeline and HIV franchise - Ad-hoc-news.de
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Cuts Target Price to $166 - Moomoo
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? - The Motley Fool
Gilead Sciences (GILD) Could Be 53% Below Fair Value After Trodelvy Approval - Sahm
The Biktarvy from Gilead SciencesHIV combo tablet grows in US use - AD HOC NEWS
Gilead Sciences Inc Stock (GILD) Closed Up by 5.35% on Jul 7: What Signal Does It Send? - TradingKey
Westwood Enhanced Income Opportunity ETF's Gilead Sciences Inc(GILD) Holding History - GuruFocus
A Look at Gilead Sciences Inc (GILD) After 5.2% Gain -- GF Value $96.06 vs Price $136.36 - GuruFocus
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MSN
Gilead Sciences rises as analyst upgrade adds to HIV franchise momentum - Quiver Quantitative
Gilead Sciences keeps building its antiviral pipeline. The focus shifts to long-term growth and US m - AD HOC NEWS
Gilead Stock Rallies As Trodelvy Wins First-Line Cancer Nod - StocksToTrade
Truist Financial Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $156 - Moomoo
Gilead Sciences patents new TIPARP inhibitors - BioWorld News
Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 - marketscreener.com
Gilead price tries to pierce ceiling of descending correctional price channelForecast today07-07-2026 - Economies.com
RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating - marketscreener.com
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
GILDGilead Sciences Inc Options - Finviz
What's Going on With Gilead Sciences Stock Monday?Gilead Sciences (NASDAQ:GILD) - Benzinga
Gilead Sciences (GILD) Participates in Ebola Treatment Clinical Trial in Congo - GuruFocus
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More - Yahoo Finance
This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Gilead Sciences stock rating upgraded to Buy by HSBC on HIV outlook - Investing.com Canada
Gilead Sciences highlights its antiviral pipeline as investors watch long-term growth potential - AD HOC NEWS
Earnings call transcript: Gilead Sciences beats Q1 2026 forecasts, stock dips - Investing.com
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel - The National Law Review
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Gilead Sciences stock faces a thin data day. Business focus stays intact. - AD HOC NEWS
Insider Sell: Daniel O'Day Sells 15,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update - marketscreener.com
Gilead Sciences Inc (GILD) Stock Up 4.2% but GF Value Says Overv - GuruFocus
Gilead (NASDAQ: GILD) CEO sells 15,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Calvert VP SRI Balanced Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says - Law360
Gilead Sciences highlights its antiviral portfolio as a long-term growth driver - AD HOC NEWS
List of 21 Acquisitions by Gilead (Jul 2026) - Tracxn
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Jun 15 '26 |
Sale |
123.92 |
3,000 |
371,762 |
124,234 |
| Dickinson Andrew D | Chief Financial Officer |
Jun 15 '26 |
Sale |
125.40 |
3,000 |
376,200 |
171,646 |
0.33%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):